Theratechnologies (TSE:TH) has released an update.
Theratechnologies has reported promising findings from its Phase 1b trial of sudocetaxel zendusortide, showing significant tumor shrinkage in patients with advanced ovarian cancer. The trial demonstrated favorable tolerability, encouraging further dose exploration. These results highlight the potential of the company’s innovative cancer treatment approach.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.